Clinical Development:ARQ 501 Phase 1 Trial

• Protocol Design: open label, single arm, non- randomized dose escalating study

of pharmacokinetics

• Indication: solid tumors

• Primary safety, clinical tolerability, and dose Endpoints: determination for Phase 2

• # Patients: 20-40 with advanced solid tumors

• Dosing: ascending I.V. dose 1x per week for 1 month

Previous slide

Next slide

Back to first slide

View graphic version